(Reuters Health) – Daily relugolix therapy cuts menstrual bleeding by at least half without affecting bone density in 71% of women with uterine fibroids, according to results from the LIBERTY 2 trial, published by The New England Journal of Medicine. The oral gonadotropin-releasing hormone (GnRH) receptor antagonist from Myovant Sciences, approved by the U.S. Food